Back to top

Delcath Systems begins dosing in Phase 2 trial of Hepzato in breast cancer

Delcath Systems (DCTH) announced that the first patient has been dosed at the European Institute of Oncology in Milan, Italy in its global Phase 2 ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Delcath Systems, Inc. (DCTH)